Sanford C. Bernstein set a €131.00 ($155.95) price target on Bayer (FRA:BAYN) in a research note published on Thursday, January 4th. The firm currently has a buy rating on the healthcare company’s stock.
Several other brokerages have also commented on BAYN. JPMorgan Chase & Co. set a €128.00 ($152.38) target price on Bayer and gave the stock a buy rating in a research report on Thursday, January 4th. Barclays set a €100.00 ($119.05) target price on Bayer and gave the stock a sell rating in a research report on Wednesday, January 3rd. Nord/LB reiterated a neutral rating on shares of Bayer in a research report on Tuesday, January 2nd. Baader Bank set a €140.00 ($166.67) target price on Bayer and gave the stock a buy rating in a research report on Thursday, December 14th. Finally, DZ Bank reiterated a buy rating on shares of Bayer in a research report on Monday, December 11th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the stock. The company has a consensus rating of Buy and an average target price of €122.33 ($145.63).
Bayer (BAYN) traded down €0.62 ($0.74) during mid-day trading on Thursday, reaching €104.86 ($124.83). The company’s stock had a trading volume of 2,223,938 shares. Bayer has a 52 week low of €99.69 ($118.68) and a 52 week high of €123.82 ($147.40). The stock has a market cap of $86,730.00 and a P/E ratio of 28.11.
TRADEMARK VIOLATION WARNING: This piece was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://ledgergazette.com/2018/01/12/bayer-bayn-given-a-131-00-price-target-at-sanford-c-bernstein-2.html.
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.